Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

on behalf of the Asia–Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis

Research output: Contribution to journalReview article

Abstract

The Asia–Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing, and future revisions are likely as new data continue to emerge.

Original languageEnglish
JournalJournal of Gastroenterology and Hepatology (Australia)
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Biosimilar Pharmaceuticals
Immunologic Factors
Biological Factors
Ulcerative Colitis
Inflammatory Bowel Diseases
Practice Guidelines
Crohn Disease
Philippines
Pharmacogenetics
Gastroenterology
Colitis
Hepatitis B
Tuberculosis
Infection

Keywords

  • adalimumab
  • biosimilar
  • Crohn's disease
  • inflammatory bowel disease
  • infliximab
  • ulcerative colitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

on behalf of the Asia–Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis (2019). Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Journal of Gastroenterology and Hepatology (Australia). https://doi.org/10.1111/jgh.14648

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. / on behalf of the Asia–Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis.

In: Journal of Gastroenterology and Hepatology (Australia), 01.01.2019.

Research output: Contribution to journalReview article

on behalf of the Asia–Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis 2019, 'Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia', Journal of Gastroenterology and Hepatology (Australia). https://doi.org/10.1111/jgh.14648
on behalf of the Asia–Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Journal of Gastroenterology and Hepatology (Australia). 2019 Jan 1. https://doi.org/10.1111/jgh.14648
on behalf of the Asia–Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. / Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. In: Journal of Gastroenterology and Hepatology (Australia). 2019.
@article{fbc0b38609784c5ba537279680756b04,
title = "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia",
abstract = "The Asia–Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing, and future revisions are likely as new data continue to emerge.",
keywords = "adalimumab, biosimilar, Crohn's disease, inflammatory bowel disease, infliximab, ulcerative colitis",
author = "{on behalf of the Asia–Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis} and Ooi, {Choon Jin} and Ida Hilmi and Rupa Banerjee and Chuah, {Sai Wei} and Ng, {Siew Chien} and Wei, {Shu Chen} and Makharia, {Govind K.} and Pises Pisespongsa and Chen, {Min Hu} and Ran, {Zhi Hua} and Ye, {Byong Duk} and Park, {Dong Il} and Ling, {Khoon Lin} and David Ong and Vineet Ahuja and Goh, {Khean Lee} and Jose Sollano and Lim, {Wee Chian} and Leung, {Wai Keung} and {Raja Ali}, {Raja Affendi} and Wu, {Deng Chyang} and Evan Ong and Nazri Mustaffa and Julajak Limsrivilai and Tadakazu Hisamatsu and Yang, {Suk Kyun} and Qin Ouyang and Richard Geary and {De Silva}, {Janaka H.} and Rungsun Rerknimitr and Marcellus Simadibrata and Murdani Abdullah and Leong, {Rupert W.L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jgh.14648",
language = "English",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

AU - on behalf of the Asia–Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis

AU - Ooi, Choon Jin

AU - Hilmi, Ida

AU - Banerjee, Rupa

AU - Chuah, Sai Wei

AU - Ng, Siew Chien

AU - Wei, Shu Chen

AU - Makharia, Govind K.

AU - Pisespongsa, Pises

AU - Chen, Min Hu

AU - Ran, Zhi Hua

AU - Ye, Byong Duk

AU - Park, Dong Il

AU - Ling, Khoon Lin

AU - Ong, David

AU - Ahuja, Vineet

AU - Goh, Khean Lee

AU - Sollano, Jose

AU - Lim, Wee Chian

AU - Leung, Wai Keung

AU - Raja Ali, Raja Affendi

AU - Wu, Deng Chyang

AU - Ong, Evan

AU - Mustaffa, Nazri

AU - Limsrivilai, Julajak

AU - Hisamatsu, Tadakazu

AU - Yang, Suk Kyun

AU - Ouyang, Qin

AU - Geary, Richard

AU - De Silva, Janaka H.

AU - Rerknimitr, Rungsun

AU - Simadibrata, Marcellus

AU - Abdullah, Murdani

AU - Leong, Rupert W.L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The Asia–Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing, and future revisions are likely as new data continue to emerge.

AB - The Asia–Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing, and future revisions are likely as new data continue to emerge.

KW - adalimumab

KW - biosimilar

KW - Crohn's disease

KW - inflammatory bowel disease

KW - infliximab

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85068412382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068412382&partnerID=8YFLogxK

U2 - 10.1111/jgh.14648

DO - 10.1111/jgh.14648

M3 - Review article

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

ER -